Teiko Bio
Teiko Bio is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
A Phase I/II Open-Label, Multi-centre Study to Assess the Safety and Tolerability of Roginolisib in Combination with an Approved JAK Inhibitor in Patients with Myelofibrosis (MF) who are Unresponsive to JAK Inhibitors (HEMA-MED)
Sponsor iOnctura SA
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase I/IIa Study of Roginolisib in combination with dostarlimab with or without docetaxel in patients with advanced non-squamous NSCLC who have progressed on standard of care immune checkpoint therapy and platinum doublet chemotherapy or standard immunotherapy without chemotherapy (PULMO-01).
Sponsor iOnctura SA
- Start (EU)
- Latest update
- Estimated end
- Not reported
A PHASE 2A, OPEN-LABEL SINGLE ARM MULTICENTER EXPLORATORY STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ORAL DOSES OF ROC-101 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (ILD-PH)
Sponsor Allrock Bio Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase II, Multi-centre, Open label, Randomised Study to Evaluate the Anti-tumour Activity of Roginolisib (IOA-244) in Patients with Advanced/Metastatic Ocular/Uveal Melanoma
Sponsor iOnctura SA
- Start (EU)
- Latest update
- Estimated end
A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured GLPG5101 (19CP02) in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma
Sponsor Lakefront Biotherapeutics
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Teiko Bio?
The 2026-10-09 snapshot links Teiko Bio to 5 distinct CTIS trials. Recorded services include Laboratory services, CYTOF analyses, CyTOF analysis. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Teiko Bio?
The most frequently recorded therapeutic areas are Haematological Malignancies, Respiratory, Solid Tumor Oncology. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Teiko Bio conducted?
The linked trials record locations in 9 countries, including Spain, Italy, Belgium, Germany, Finland. These are trial locations, not confirmed office locations or countries where Teiko Bio delivered services.
What can this page tell me about Teiko Bio's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Teiko Bio. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Teiko Bio Inc.